These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 10639513)

  • 1. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
    van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
    J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
    Brinkman A; van der Flier S; Kok EM; Dorssers LC
    J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas.
    van der Flier S; Chan CM; Brinkman A; Smid M; Johnston SR; Dorssers LC; Dowsett M
    Int J Cancer; 2000 Sep; 89(5):465-8. PubMed ID: 11008210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue.
    van der Flier S; van der Kwast TH; Claassen CJ; Timmermans M; Brinkman A; Henzen-Logmans SC; Foekens JA; Dorssers LC
    Int J Biol Markers; 2001; 16(3):172-8. PubMed ID: 11605729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How is tamoxifen's action subverted?
    Jordan VC
    J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
    [No Abstract]   [Full Text] [Related]  

  • 7. The prognostic value of BCAR1 in patients with primary breast cancer.
    Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells.
    Brinkman A; de Jong D; Tuinman S; Azaouagh N; van Agthoven T; Dorssers LC
    Breast Cancer Res Treat; 2010 Apr; 120(2):401-8. PubMed ID: 19412734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
    J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.